› Forums › Cutaneous Melanoma Community › A_Melanoma_Molecular_Disease_Model
- This topic has 4 replies, 2 voices, and was last updated 13 years, 11 months ago by
JerryfromFauq.
- Post
-
- October 2, 2011 at 8:33 am
This is a great article that discuses melanoma signaling pathways, the molecular drivers of this disease, molecular subtypes and developing proposed treatment guidelines for each subtype, including specific assays, drugs, and clinical trials. labs that conduct various tests, etc. This information is written at a layman level and is fairly easy to follow.
This is a great article that discuses melanoma signaling pathways, the molecular drivers of this disease, molecular subtypes and developing proposed treatment guidelines for each subtype, including specific assays, drugs, and clinical trials. labs that conduct various tests, etc. This information is written at a layman level and is fairly easy to follow.
Drug Company
Status
Clinical Trial
Target
I have only posted the Abstract here. The real meat is at the URL.
http://mmdm.cancercommons.org/ml/index.php/A_Melanoma_Molecular_Disease_Model
I. Abstract
While advanced melanoma is one of the most challenging cancers to treat, recent developments in our understanding of the molecular drivers of this disease have uncovered exciting opportunities to guide personalized therapy decisions. Genetic analysis of melanoma have uncovered several key molecular pathways that are involved in disease onset, progression as well as prognosis. These advances now make possible classification of melanoma into molecular subtypes (unlike traditional histological subtypes), with proposed treatment guidelines for each subtype, including specific assays, drugs, and clinical trials.
This paper outlines such a 'molecular disease model' that can be used by both researchers and clinicians- clinicians could use it a guide in their therapy decisions and contribute to it with real-life patient outcomes data whereas researchers could refine molecular subtypes based on their findings and use clinical outcomes data to guide their research. This 'dynamic' paper will reflect latest scientific, clinical and technological advancements by providing a rapid process for submission, contextualization and dissemination of information and data.
- Replies
-
-
- October 2, 2011 at 9:28 pm
Hey Jerry!? Is that you?
Your profile says you were killed in a horse accident? Are you a zombie now!
Stop horsing around.
-
- October 3, 2011 at 5:59 am
They wanted to remove my organs. Gave no chancr of my surviving overnight for a week. My grandkids have me be the Zoombie in their games. Still willig to ride horses. BUT not with slick shoes!
-
- October 3, 2011 at 5:59 am
They wanted to remove my organs. Gave no chancr of my surviving overnight for a week. My grandkids have me be the Zoombie in their games. Still willig to ride horses. BUT not with slick shoes!
Tagged: cutaneous melanoma
- You must be logged in to reply to this topic.